Calcium and magnesium infusions for the prevention of oxaliplatin-induced peripheral neurotoxicity: A systematic review

Oncology (Switzerland)

Volumn 90, Issue 6, 2016, Pages 299-306

  Jordan, Berit ^a   Jahn, Franziska ^a   Beckmann, Juliane ^a   Unverzagt, Susanne ^a   Müller Tidow, Carsten ^a   Jordan, Karin ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Calcium and magnesium infusion; National Cancer Institute Common Terminology Criteria for Adverse Events; Oxaliplatin; Peripheral neuropathy; Supportive care

Indexed keywords

CALCIUM; MAGNESIUM; OXALIPLATIN; ANTINEOPLASTIC AGENT; CALCIUM DERIVATIVE; MAGNESIUM DERIVATIVE; PLATINUM COMPLEX;

DRUG EFFICACY; DRUG INFUSION; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PERIPHERAL NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHEMICALLY INDUCED; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS (TOPIC); PERIPHERAL NERVOUS SYSTEM DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; CALCIUM COMPOUNDS; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MAGNESIUM COMPOUNDS; META-ANALYSIS AS TOPIC; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84967166942     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000445977     Document Type: Review

References (21)

1. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30: 5-13.
2. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol 2015; 33: 3416-3422.
3. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014; 3: CD005228.
4. Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10: 4055-4061.
5. Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL. Calcium and magnesium use for oxaliplatin-induced neuropathy: a case study to assess how quickly evidence translates into practice. J Natl Compr Canc Netw 2015; 13: 1097-1101.
6. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29: 421-427.
7. Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, Mol L, Vincent AD, Teerenstra S, Punt CJ. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47: 369-374.
8. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 2010; 15: 82-87.
9. Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, Koo WH, Choo SP. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol 2010; 6: 270-277.
10. Dong M, Xing PY, Liu P, Feng FY, Shi YK. Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity (in Chinese). Zhonghua Zhong Liu Za Zhi 2010; 32: 208-211.
11. Hochster H, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of the CONcePT trial. Ann Oncol 2014; 25: 1172-1178.
12. Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, Du ZD, Dai J, Li Q. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-Analysis. Ann Oncol 2013; 24: 171-178.
13. Wu Z, Ouyang J, He Z, Zhang S. Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-Analysis. Eur J Cancer 2012; 48: 1791-1798.
14. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/alliance). J Clin Oncol 2014; 32: 997-1005.
15. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, Schunemann HJ. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 2013; 66: 158-172.
16. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269, W264.
18. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-1189; author reply 1189-1190.
19. Chaves J, Patel K, Abdelghany O, Coleman C, Lacy J, Hochster HS. Outcome of intravenous calcium and magnesium (Ca/Mg) in oxaliplatin-containing regimens compared with no Ca/Mg. J Clin Oncol 2011; 29(suppl): 19681.
20. Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, Yamamoto Y, Suzuki S, Asama T, Kamiya K. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med 2011; 2011: 418481.
21. Kono T, Mishima H, Shimada M, Morita S, Sakamoto J; GONE Investigators. Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE study). Jpn J Clin Oncol 2009; 39: 847-849.